KR101866924B1 - Composition for improving metabolism disorder comprising syringaresinol - Google Patents
Composition for improving metabolism disorder comprising syringaresinol Download PDFInfo
- Publication number
- KR101866924B1 KR101866924B1 KR1020110108904A KR20110108904A KR101866924B1 KR 101866924 B1 KR101866924 B1 KR 101866924B1 KR 1020110108904 A KR1020110108904 A KR 1020110108904A KR 20110108904 A KR20110108904 A KR 20110108904A KR 101866924 B1 KR101866924 B1 KR 101866924B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- expression
- fatty acid
- sirling
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 title claims description 4
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 title claims description 4
- 208000030159 metabolic disease Diseases 0.000 title description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 241000208340 Araliaceae Species 0.000 claims description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 17
- 235000008434 ginseng Nutrition 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 150000004665 fatty acids Chemical class 0.000 claims description 16
- 230000003647 oxidation Effects 0.000 claims description 15
- 238000007254 oxidation reaction Methods 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 14
- 235000020824 obesity Nutrition 0.000 claims description 14
- 208000004930 Fatty Liver Diseases 0.000 claims description 11
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 11
- 208000010706 fatty liver disease Diseases 0.000 claims description 11
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000004136 fatty acid synthesis Effects 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 claims description 5
- 235000004426 flaxseed Nutrition 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 description 34
- 241000282414 Homo sapiens Species 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000001789 adipocyte Anatomy 0.000 description 17
- 235000013399 edible fruits Nutrition 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 15
- 210000000107 myocyte Anatomy 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 229940056692 resinol Drugs 0.000 description 9
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 8
- 102000011990 Sirtuin Human genes 0.000 description 8
- 108050002485 Sirtuin Proteins 0.000 description 8
- 108010041191 Sirtuin 1 Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000207961 Sesamum Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000037149 energy metabolism Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 244000043261 Hevea brasiliensis Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 2
- 102100034033 Alpha-adducin Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000799076 Homo sapiens Alpha-adducin Proteins 0.000 description 2
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 2
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 2
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101000629598 Rattus norvegicus Sterol regulatory element-binding protein 1 Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020805 dietary restrictions Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- -1 lignan compound Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 시링가레시놀을 유효 성분으로 포함하는 대사 이상증 예방 또는 개선용 조성물을 개시한다.The present invention discloses a composition for the prevention or amelioration of metabolic dysfunction comprising Sirling's resinoid as an active ingredient.
Description
본 발명은 시링가레시놀을 포함하는 대사 이상증 개선용 조성물에 관한 것이다.
The present invention relates to a composition for improving metabolic dysfunction comprising Sirling's lysinol.
문명의 이기로 인한 생활 방식의 변화와 넘쳐나는 고칼로리 식품으로 인해 인류는 비만, 제2형 당뇨병, 고지혈증, 지방간 등으로 대표되는 대사성 질환의 위험에 노출되어 있다. 그 중에서 비만이 제2형 당뇨병, 고지혈증, 지방간과 같은 대사성 질환의 주요 원인임을 감안할 때, 비만을 예방 또는 개선하면 그 외 대사성 질환도 예방할 수 있을 것이다.Due to changes in lifestyle and overflowing high calorie food, human beings are exposed to the risk of metabolic diseases such as obesity,
비만은 일반적으로 체내 에너지 소비에 비해 에너지 유입이 많아지는 경우에 발생한다. 구체적으로, 잉여 에너지는 트리글리세리드(Triglyceride)의 형태로 지방 조직에 저장된다. 지방 조직은 마치 고무 풍선과 같이 많은 양의 잉여 에너지를 저장할 수 있지만, 그와 동시에 지방세포의 크기를 증가시킨다. 또한 저장되어야 하는 잉여 에너지의 양이 지방 조직만으로 감당이 안될 경우 근육, 간 등의 기타 조직에 에너지가 저장되는 지질 이상 조절(lipid dysregulation)이 발생하고 지방 독성(lipotoxicity)이 나타난다. 또한 각 조직에 저장된 지방은 지방 분해 (lipolysis)를 통하여 유리 지방산(free fatty acid)으로 변하는데, 이 유리 지방산은 JNK, PKC 등의 신호 전달 기전을 통하여 인슐린 신호 전달 체계를 무력화시킨다고 알려져 있다. 인슐린 신호 전달 체계의 저해는 필연적으로 인슐린 저항성을 야기하고, 이로 인해 고혈당증, 고지혈증, 고콜레스테롤증, 제2형 당뇨병, 지방간 등 다양한 대사성 질환이 유발된다. 이렇듯 비만은 단순히 외형상의 문제뿐 아니라 각종 성인성 질병을 동반하기 때문에 더욱 심각하다고 할 수 있다.
Obesity generally occurs when the energy input is greater than the energy expenditure in the body. Specifically, the surplus energy is stored in adipose tissue in the form of triglycerides. Adipose tissue can store large amounts of surplus energy, such as rubber balloons, but at the same time increases the size of adipocytes. In addition, if the amount of surplus energy to be stored is not covered by fat tissue alone, lipid dysregulation occurs in which energy is stored in other tissues such as muscle, liver, and lipotoxicity. In addition, fat stored in each tissue is transformed into free fatty acid through lipolysis. This free fatty acid is known to neutralize insulin signaling through signal transduction mechanisms such as JNK and PKC. Inhibition of the insulin signaling system inevitably leads to insulin resistance, which leads to various metabolic diseases such as hyperglycemia, hyperlipidemia, hypercholesterolemia,
본 발명은 뛰어난 대사 이상증 예방 또는 개선 효과, 구체적으로 지방 대사를 조절함으로써 뛰어난 대사 이상증 예방 또는 개선 효과를 가지는 조성물을 제공하고자 한다. 또한 본 발명은 뛰어난 대사 이상증 예방 또는 개선 효과를 가지는 식품 및 약학 조성물을 제공하고자 한다.
The present invention aims to provide a composition having excellent metabolic dysfunction prevention or improvement effect, specifically preventing or improving metabolic dysfunction by controlling lipid metabolism. The present invention also provides a food and pharmaceutical composition having an excellent metabolic dysfunction prevention or improvement effect.
본 발명의 일측면은 시링가레시놀(syringaresinol)을 유효 성분으로 포함하는 대사 이상증 예방 또는 개선용 조성물을 제공한다.An aspect of the present invention provides a composition for preventing or ameliorating metabolic dystrophy comprising syringaresinol as an active ingredient.
본 발명의 다른 일측면은 시링가레시놀을 유효 성분으로 포함하는 대사 이상증 예방 또는 개선용 식품 및 약학 조성물을 제공한다.
Another aspect of the present invention provides a food and pharmaceutical composition for preventing or ameliorating metabolic dystrophy which comprises Sirling's resinoid as an active ingredient.
본 발명에 따른 조성물은 시링가레시놀을 유효 성분으로 포함함으로써, SIRT 1(Sirtuin 1)의 발현을 증가시키고, 지방산 합성을 억제함과 동시에 지방산 산화를 촉진하며, PGC 1의 발현을 증가시킴으로써, 대사 이상증, 구체적으로 비만, 제2형 당뇨병, 고지혈증 또는 지방간을 예방 및 개선하는 효과가 뛰어나다.
The composition according to the present invention increases the expression of SIRT 1 (Sirtuin 1), inhibits fatty acid synthesis, accelerates fatty acid oxidation and increases the expression of PGC 1 by incorporating Siring Gelsinol as an active ingredient, Metabolic dysfunction, specifically obesity,
도 1은 인삼 열매 추출물로부터 시링가레시놀을 분리 및 정제하는 방법을 나타낸 개략도이다.
도 2는 시링가레시놀의 화학 구조이다.
도 3은 시링가레시놀 20, 50, 100 μM을 인간 지방세포, 간세포 및 근세포에 처리한 후 SIRT 1 유전자의 발현 변화를 나타낸 그래프이다.
도 4는 시링가레시놀 50 μM을 처리한 인간 지방세포에서 지방산 합성에 관련된 유전자들의 발현 감소량을 나타낸 그래프이다.
도 5는 시링가레시놀 50 μM을 처리한 인간 간세포에서 지방산 합성에 관련된 유전자들의 발현 감소량을 나타낸 그래프이다.
도 6은 시링가레시놀 50 μM을 처리한 인간 근세포에서 지방산 합성에 관련된 유전자들의 발현 감소량을 나타낸 그래프이다.
도 7은 시링가레시놀 50 μM을 처리한 인간 지방세포에서 지방산 산화에 관련된 유전자들의 발현 증가량을 나타낸 그래프이다.
도 8은 시링가레시놀 50 μM을 처리한 인간 간세포에서 지방산 산화에 관련된 유전자들의 발현 증가량을 나타낸 그래프이다.
도 9는 시링가레시놀 50 μM을 처리한 인간 근세포에서 지방산 산화에 관련된 유전자들의 발현 증가량을 나타낸 그래프이다.
도 10 시링가레시놀 50 μM을 처리한 인간 지방세포, 간세포 및 근세포에서 지방산 산화가 증가됨을 나타낸 그래프이다.
도 11은 시링가레시놀 50 μM을 처리한 인간 지방세포, 간세포 및 근세포에서 에너지 대사 조절 유전자인 PGC 1a의 발현 증가 정도를 나타낸 그래프이다.
도 12는 시링가레시놀 50 μM을 처리한 인간 지방세포, 간세포 및 근세포에서 에너지 대사 조절 유전자인 PGC 1b의 발현 증가 정도를 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic view showing a method for separating and purifying Siringagrelin from a ginseng fruit extract. FIG.
Figure 2 is the chemical structure of Sirling's lycinol.
FIG. 3 is a graph showing changes in the expression of
FIG. 4 is a graph showing the amount of decrease in the expression of genes involved in fatty acid synthesis in human adipocytes treated with 50 μM Sirling's resinol. FIG.
FIG. 5 is a graph showing a decrease in the expression levels of genes involved in fatty acid synthesis in human hepatocytes treated with 50 μM Sirling's resinol. FIG.
FIG. 6 is a graph showing the decrease in the expression levels of genes involved in fatty acid synthesis in human myocytes treated with 50 .mu.M Sirengarceinol.
FIG. 7 is a graph showing an increase in the expression levels of genes involved in fatty acid oxidation in human adipocytes treated with 50 μM Sirengarceinol. FIG.
FIG. 8 is a graph showing the increase in expression of genes involved in fatty acid oxidation in human hepatocytes treated with 50 μM Sirling's resinol. FIG.
FIG. 9 is a graph showing an increase in the expression levels of genes involved in fatty acid oxidation in human myocytes treated with 50 μM Sirlinggarisin.
FIG. 10 is a graph showing that fatty acid oxidation is increased in human adipocytes, hepatocytes and myocytes treated with 50 mg of Ringer's Resinol.
FIG. 11 is a graph showing the degree of increase in the expression of PGC 1a, an energy metabolism-regulating gene in human adipocytes, hepatocytes and muscle cells treated with 50 μM Sirling's resinol.
FIG. 12 is a graph showing the degree of increase in expression of PGC 1b, an energy metabolism control gene, in human adipocytes, hepatocytes and myocytes treated with 50 μM Sirling's resinol.
본 명세서에서 “추출물"은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 천연물의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 광범위한 개념이다.
As used herein, the term " extract "is a broad concept that encompasses all of the substances obtained by extracting components of natural products, regardless of the type of extraction method, extraction solvent, extracted component or extract.
지방 대사를 조절하는 경우 지방의 과다 축적을 방지할 수 있으므로 비만을 예방 및 개선할 수 있을 것이다. 지방의 과다 축적을 방지하는 방법 중 하나로 식이 제한, 즉 칼로리 제한을 들 수 있다. 식이를 제한하면 체중을 감소시킬 수 있을 뿐 아니라 혈중 지질 농도를 개선하여 대사성 질환을 개선할 수 있다. 식이를 제한하는 경우 SIRT 1(Sirtuin 1, 시르투인 1) 단백질의 발현이 증가하며, 나아가 식이 제한을 하지 않아도 SIRT 1의 활성 증가를 유도하는 경우 식이 제한을 한 경우와 비슷한 현상이 나타나는 것으로 알려져 있다. SIRT 1은 포도당 합성, 지방산 산화 등과 같은 에너지 대사를 조절하는 NAD+-의존적 히스톤 단백질 탈아세틸화효소이다. 따라서 SIRT 1의 발현을 조절할 수 있는 물질은 지방 대사를 조절할 수 있고, 나아가 비만, 제2형 당뇨병, 고지혈증, 지방간을 예로 들 수 있는 대사 이상증을 예방 또는 개선할 수 있을 것이다.
When controlling the fat metabolism, excessive accumulation of fat can be prevented, so that obesity can be prevented and improved. One way to prevent overaccumulation of fat is dietary restriction, that is, calorie restriction. Limiting diet can not only reduce body weight but also improve blood lipid levels and improve metabolic diseases. It is known that the expression of SIRT 1 (Sirtuin 1, sirtuin 1) protein is increased when the diet is restricted, and when
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 대사 이상증 예방 또는 개선용 조성물을 제공한다.One aspect of the present invention provides a composition for preventing or ameliorating metabolic dystrophy, which comprises Sirling's resinoid as an active ingredient.
생명체는 생명을 유지하지 위하여 영양소를 섭취하고, 그것을 소화 흡수하여 체성분으로 하며, 에너지원으로 저장한다. 또한 이를 분해하여 그 때 유리되는 에너지로 각종 생체 활동을 행하는데, 이와 같은 현상을 “대사”라고 한다. 본 명세서에서, “대사 이상증”이란 인간 또는 동물을 포함하는 생명체가 상기 대사 활동을 원활하게 행할 수 없게 된 상태를 의미하며, 당질 대사 이상증 또는 지질 대사 이상증을 포함한다. 당질 대사 이상 또는 지질 대사 이상은 당질 또는 지질 대사 장애에 기인한 증상 또는 질환, 구체적으로 지방산 대사 장애에 기인한 지방 과다 축적으로 인한 증상 또는 질환을 포함하며, 이의 예로는 비만, 제2항 당뇨병, 고지혈증 또는 지방간을 들 수 있다.Life consumes nutrients to maintain life, digests and absorbs them to make body components, and stores them as energy sources. In addition, it disassembles it and performs various bio-activities with the energy liberated at that time. Such a phenomenon is called "metabolism". As used herein, the term " metabolic disorder " means a state in which a living being including a human or an animal is unable to perform the metabolism smoothly, and includes a glucose metabolism disorder or a lipid metabolism disorder. A lipid metabolism abnormality or a lipid metabolism abnormality includes a symptom or a disease caused by a hyperglycemia or lipid metabolism disorder, specifically, a lipid accumulation-caused symptom or a disease caused by a fatty acid metabolic disorder, examples of which include obesity, diabetes mellitus, Hyperlipemia or fatty liver.
시링가레시놀은 도 2와 같은 화학 구조를 가지는 리그난계 화합물로, 화학 합성을 통해 얻거나, 아마씨, 황백, 가시오가피, 참깨 및 인삼 열매 중 하나 이상으로부터 추출할 수 있다. 상기 아마씨, 황백, 가시오가피 및 참깨는 각 식물의 잎, 줄기, 뿌리, 열매 또는 씨를 예로 들 수 있는 식물의 각 부위를 모두 포함하며, 인삼 열매는 인삼 열매 과피 또는 과육을 포함한다.Siringar Recinol is a lignan compound having the chemical structure shown in FIG. 2, which can be obtained through chemical synthesis or extracted from one or more of flaxseed, white, white, sesame and ginseng. The above flaxseed, yellow, white, and sesame seeds include all parts of a plant such as leaf, stem, root, fruit or seed of each plant, and the ginseng fruit includes ginseng fruit rind or flesh.
시링가레시놀은 SIRT 1의 발현을 증가시키고, 지방산 합성을 억제함과 동시에 지방산의 산화를 촉진하여 체내 지방 축적을 저지할 수 있다. 이는 시링가레시놀이 ADD1/SREBP1c, ACC, FAS와 같은 지방산 합성 관련 유전자의 발현을 억제하고, ACO, CPT1, mCAD과 같은 지방산 산화 관련 유전자의 발현을 촉진하며, 지방산 산화를 증가시키는 것으로부터 확인될 수 있다. 또한 시링가레시놀은 에너지 대사, 구체적으로 지방 대사를 촉진하여 체내 지방 소비를 증대시키고 잉여 지방의 축적을 저지할 수 있는데, 이는 시링가레시놀이 에너지 대사에 관련된 유전자들의 발현을 조절하는 PGC(peroxisome proliferator-activated receptor coactivator) 1의 발현을 증가시킨다는 것으로부터 확인될 수 있다. 따라서 시링가레시놀을 포함하는 조성물은 당질 또는 지질 대사 장애에 기인한, 비만, 제2항 당뇨병, 고지혈증 또는 지방간과 같은 대사 이상증을 예방 또는 개선할 수 있다.Sirring regicin increases the expression of
본 발명의 일측면에서, 시링가레시놀은 아마씨, 황백, 가시오가피, 참깨 및 인삼 열매 중 하나 이상을 물, 유기 용매 및 물과 유기 용매의 혼합물로 이루어진 군에서 선택된 하나 이상으로 추출하여 수득할 수 있다. 상기 유기 용매는 알코올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다. 상기 알코올은 C1~C5의 저급 알코올을 포함하며, C1~C5의 저급 알코올은 메탄올, 에탄올, 이소프로필알코올, n-프로필알코올, n-부탄올 및 이소부탄올로 구성된 군으로부터 선택되는 하나 이상을 포함하나, 이에 제한되는 것은 아니다.In one aspect of the present invention, Siringaglisinol can be obtained by extracting at least one of flaxseed, yellowtail, sesame gum, sesame and ginseng fruit with at least one selected from the group consisting of water, an organic solvent and a mixture of water and an organic solvent have. The organic solvent includes, but is not limited to, at least one selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform. Wherein the alcohol comprises a C 1 to C 5 lower alcohol and the C 1 to C 5 lower alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol and isobutanol But is not limited thereto.
본 발명의 다른 일측면에서, 시링가레시놀은 아마씨, 황백, 가시오가피, 참깨 및 인삼 열매의 추출물로 조성물에 포함될 수 있으며, 그 중 대사 이상증 개선에 특히 효과적인 분획이 포함될 수 있다.In another aspect of the present invention, the Sirling's lecithin may be contained in the composition as an extract of flaxseed, yellowtail, sesame, sesame and ginseng fruit, among which a fraction particularly effective for the improvement of the metabolic dysfunction may be included.
본 발명의 일측면에서, 시링가레시놀을 인삼 열매로부터 분리 및 정제하는 방법은 다음과 같은 단계를 포함할 수 있다. 인삼 열매 과육의 알코올 추출물을 제조하는 단계; 제조한 알코올 추출물을 물과 알코올 중 하나 이상을 포함하는 용매로 용출시켜 분획을 수득하는 단계; 및 수득한 분획에 대해 유기 용매를 전개 용매로 사용하여 크로마토그래피, 구체적으로 얇은 막 크로마토그래피(TLC)를 수행하는 단계. 상기에서 유기 용매는 알코올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하며, 알코올은 C1~C5의 알코올을 포함한다. 본 발명의 일측면에 따른 조성물은 상기와 같이 정제된 시링가레시놀을 유효 성분으로 포함할 수 있다.In one aspect of the present invention, a method for separating and purifying Sirling's lycinol from ginseng fruit may comprise the following steps. Preparing an alcoholic extract of the ginseng fruit pulp; Eluting the alcohol extract with a solvent containing at least one of water and alcohol to obtain a fraction; And performing chromatography, specifically Thin Film Chromatography (TLC), on the obtained fractions using an organic solvent as a developing solvent. The organic solvent includes at least one selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform, and the alcohol includes C 1 to C 5 alcohols. The composition according to one aspect of the present invention may contain the purified syringes lecinol as an active ingredient as described above.
본 발명의 일측면에 따른 조성물은 조성물 전체 중량을 기초로 1 중량% 내지 80 중량%, 구체적으로 5 중량% 내지 60 중량%, 더 구체적으로 10 중량% 내지 30 중량%의 시링가레시놀을 포함할 수 있다. 상기 범위로 포함하는 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 상기 범위로 사용하는 것이 적절할 수 있다. 구체적으로 시링가레시놀이 1 중량% 미만인 경우 충분한 대사 이상증 개선 효과를 얻을 수 없고, 80 중량%를 초과하는 경우 안전성 및 제형 안정성이 낮아질 수 있다.
The composition according to one aspect of the present invention comprises from 1% to 80% by weight, in particular from 5% to 60% by weight, more specifically from 10% to 30% by weight, based on the total weight of the composition, can do. When it is included in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both the stability and safety of the composition and may be suitably used within the above range in terms of cost effectiveness. Concretely, when the amount of Sirling's Lysinol is less than 1% by weight, the sufficient effect of improving metabolic dysfunction can not be obtained. When it exceeds 80% by weight, safety and formulation stability may be lowered.
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 식품 조성물을 제공한다. 상기 식품 조성물은 비만, 제2항 당뇨병, 고지혈증 또는 지방간과 같은 대사 이상증을 예방 또는 개선할 수 있으며, 기호 식품 또는 건강 식품 조성물을 포함한다.One aspect of the present invention provides a food composition comprising Sirling's resinol as an active ingredient. The food composition can prevent or ameliorate metabolic syndrome such as obesity, second-line diabetes, hyperlipidemia or fatty liver, and includes a preference food or health food composition.
상기 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 분말제, 드링크제와 같은 액제, 캐러멜, 겔, 바 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The formulation of the food composition is not particularly limited, but may be formulated into, for example, tablets, granules, powders, liquid preparations such as drinks, caramels, gels, bars and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1 mg/kg/일 내지 5000 mg/kg/일, 보다 구체적으로는 50 mg/kg/일 내지 500 mg/kg/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등 다양한 요인에 따라 달라질 수 있다.
Determination of the dosage of the active ingredient is within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day to 500 mg / kg / day, but it is not limited thereto, and may be varied depending on various factors such as the age, health condition, and complication of the subject to be administered.
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 약학 조성물을 제공한다. 상기 약학 조성물은 대사 이상증을 예방 또는 개선할 수 있으며, 구체적으로 비만, 제2항 당뇨병, 고지혈증 또는 지방간을 예방 또는 개선할 수 있다.One aspect of the present invention provides a pharmaceutical composition comprising Sirling's rescinol as an active ingredient. The pharmaceutical composition can prevent or ameliorate metabolic dysfunction, and specifically can prevent or ameliorate obesity, diabetes mellitus, hyperlipidemia or fatty liver.
본 발명의 일측면에 따른 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다.The pharmaceutical composition according to one aspect of the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.
경구 투여를 위한 제형은 정제(錠劑), 환제(丸劑), 연질 및 경질 캅셀제, 과립제(顆粒劑), 산제, 세립제, 액제, 유탁제(乳濁濟) 또는 펠렛제일 수 있으나, 이에 제한되는 것은 아니다. 이들 제형은 유효 성분 이외에 희석제(예: 락토오스, 덱스트로오스, 수크로오스, 만니톨, 솔비톨, 셀룰로오스 또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 또는 폴리에틸렌 글리콜), 또는 결합제(예: 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카르복시메틸셀룰로오스 또는 폴리비닐피롤리딘)를 함유할 수 있다. 경우에 따라 붕해제, 흡수제, 착색제, 향미제, 또는 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Formulations for oral administration may be in the form of tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets, It is not. These formulations may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine, a lubricant such as silica, talc, stearic acid or polyethylene glycol, or a binder such as magnesium aluminum Silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). And may optionally contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners. The tablets may be prepared by conventional mixing, granulating or coating methods.
비경구 투여를 위한 제제는 주사제, 점적제, 로션, 연고, 겔, 크림, 현탁제, 유제, 좌제(坐劑), 패취 또는 분무제일 수 있으나, 이에 제한되는 것은 아니다.Formulations for parenteral administration may be, but are not limited to, injections, drops, lozenges, ointments, gels, creams, suspensions, emulsions, suppositories, patches or spraying agents.
본 발명의 일측면에 따른 약학 조성물의 유효 성분은 투여 받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1 mg/kg/일 내지 100 mg/kg/일, 보다 구체적으로는 5 mg/kg/일 내지 50 mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.
The effective ingredients of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, route of administration, or judgment of the prescriber. Determination of the amount of application based on these factors is within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day. < / RTI >
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 화장료 조성물을 제공한다. 상기 화장료 조성물은 대사 이상증을 예방 또는 개선할 수 있으며, 구체적으로 비만, 제2항 당뇨병, 고지혈증 또는 지방간을 예방 또는 개선할 수 있다.One aspect of the present invention provides a cosmetic composition comprising Sirling's recinol as an active ingredient. The cosmetic composition can prevent or ameliorate metabolic dysfunction, and can specifically prevent or ameliorate obesity, diabetes, hyperlipidemia or fatty liver.
본 발명에 따른 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition according to the present invention may be provided in all formulations suitable for topical application. For example, it may be provided as a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an oil phase in water, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한(制汗)제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.
The cosmetic composition according to the present invention may further comprise a moisturizing agent, an emollient agent, a surfactant, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjusting agent, organic and inorganic pigments, a fragrance, . The compounding amount of the above components can be easily selected by those skilled in the art within a range not to impair the objects and effects of the present invention. The amount thereof may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight, have.
이하, 실시예 및 실험예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나, 이들 실시예 및 실험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 그에 의해 제한되는 것은 아니다.
Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to Examples and Experimental Examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
[실시예] 시링가레시놀의 분리 및 분석EXAMPLES Isolation and Analysis of Syringal Resinol
1. 인삼 열매의 전처리1. Pretreatment of ginseng fruit
생(生) 인삼 열매를 수확하고, 종자를 분리하여 제거한 후, 인삼 열매의 과피를 제거하고 과육만을 일광 건조 또는 열풍 건조 하여 인삼 열매 과육 건조물을 제조하였다.
The raw ginseng fruit was harvested and the seeds were separated and removed. Then, the ginseng fruit was removed, and only the flesh was dried with sunlight or hot air to produce dried ginseng fruit pulp.
2. 인삼 열매 과육 추출물로부터 시링가레시놀의 분리 및 분석2. Isolation and Analysis of Syringal Resinol from Extracts of Fruits and Ginseng Fruits
상기에서 제조한 인삼 열매 과육 건조물 1 kg에 물 또는 주정 3L를 가하여 상온 또는 환류 추출하고 여과한 다음 40~45 ℃에서 감압 농축하여 인삼 열매 과육 추출물 300 g을 얻었다. 추출물에 에테르(ether)를 처리하여 지용성 성분을 제거한 후, 부탄올(butanol)로 조사포닌을 추출 및 농축하였다. 이를 분리, 정제하여 시링가레시놀을 얻었으며, 구체적인 방법은 다음과 같다. 먼저 시료 194 g을 역상 컬럼 크로마토그래피(reversed-phase column chromatography)로 정제하였으며, 이때 용출 용매로 처음에는 100% 물을 사용하였고 메탄올을 10%씩 점차 증가시켜 최종적으로는 100% 메탄올 용매를 사용하였다. 그 결과 GB-1 내지 GB-10 분획물을 얻었으며, 이들 분획물 중 SIRT 1 발현 활성을 나타낸 분획 GB-3을 선별하여 농축한 후 50% 수용성 메탄올(aqueous methanol)을 이용하여 세파덱스 LH-20 컬럼 크로마토그래피(Sephadex LH-20 column chromatography)를 수행하였다. 얻은 분획물 중 SIRT 1 발현 활성을 나타낸 GB-3-6(3F)을 선별하여 농축한 후, 클로로포름:메탄올(10:1)을 전개 용매로 예비 실리카겔(preparative silica gel) TLC를 수행하였고, 그 결과 Rf값 0.67의 활성 분획을 정제하였다. 상기 분리 및 정제 방법을 도식화하여 도 1에 나타내었다.To 1 kg of dried ginseng fruit pulp prepared above, 3 liters of water or alcohol was added, and the mixture was extracted at room temperature or reflux, filtered, and concentrated under reduced pressure at 40 to 45 ° C to obtain 300 g of ginseng fruit pulp extract. The extract was treated with ether to remove lipid soluble components, crude saponin was extracted with butanol and concentrated. This was separated and purified to obtain syringal lysinol. Specific methods are as follows. First, 194 g of the sample was purified by reversed-phase column chromatography. 100% water was initially used as the elution solvent, methanol was gradually increased by 10%, and finally 100% methanol solvent was used . As a result, GB-1 to GB-10 fractions were obtained. The fractions GB-3 showing the SIRT1 expression activity were selected and concentrated. Then, 50% aqueous methanol was used to separate the fractions from the Sephadex LH-20 column Followed by chromatography (Sephadex LH-20 column chromatography). GB-3-6 (3F) showing the SIRT1 expression activity was selected and concentrated. TLC of preparative silica gel was performed using chloroform: methanol (10: 1) as a developing solvent. The active fraction having an Rf value of 0.67 was purified. The separation and purification method is schematically shown in FIG.
NMR 분광 분석과 데이터베이스 검색을 수행하여 분리 및 정제한 활성 화합물을 시링가레시놀(syringaresinol)로 동정할 수 있었다. 이를 재확인하기 위하여 질량(mass) 분석을 수행하였으며, ESI-mass를 positive mode에서 측정한 결과 [M+Na]+가 m/z 440.9에서, [2M+Na]+가 m/z 858.9에서 관찰되어 분자량이 418임을 알 수 있었다. 또한 NMR 분광 분석을 수행하여 화학 구조를 결정하였으며, 그 결과는 도 2와 같다. 도 2에서 볼 수 있듯이, 분리 및 정제한 활성 화합물은 시링가레시놀의 화학 구조를 가지고 있다.NMR spectroscopic analysis and database search were performed to identify the active compound isolated and purified as syringaresinol. Mass spectrometry was performed to confirm this. ESI-mass was measured in positive mode, and [M + Na] + was observed at m / z 440.9 and [2M + Na] + at m / z 858.9 The molecular weight was found to be 418. NMR spectroscopy was also performed to determine the chemical structure, and the results are shown in FIG. As can be seen in Fig. 2, the active compound isolated and purified has the chemical structure of siringa regicinol.
이와 같이 인삼 열매 과육으로부터 시링가레시놀을 분리하였다.
In this way, singlingcecinol was isolated from the ginseng fruit pulp.
[실험예 1] 지방세포, 간세포 및 근세포에서 SIRT 1 발현 촉진 효과 평가[Experimental Example 1] Evaluation of promoting effect of SIRT1 expression in adipocytes, hepatocytes and myocytes
시링가레시놀의 인간 지방세포(adipocyte), 간세포(hepacyte) 및 근세포(myocyte)에서의 SIRT 1 유전자 발현 촉진 효과를 평가하기 위하여, 아래와 같은 실험을 수행하였다.The following experiments were performed to evaluate the promoting effect of
인간 지방세포, 간세포 및 근세포는 젠바이오(ZENBIO, Research Triangle Park, NC, USA)로부터 구입하여, 각각 지방세포 전용배지(OM-AM, ZENBIO), 간세포 전용배지 (HM-2, ZENBIO) 및 근세포 전용 배지(SKM-D, SKM-M, ZENBIO)를 이용하여 5% CO2 배양기에서 배양하였다. 각 세포에, DMSO에 녹인 시링가레시놀을 20, 50, 100 μM 농도로 24시간 처리하였고, 음성 대조군에는 배지 부피 1/1000의 DMSO를 처리하였다.Human adipocytes, hepatocytes, and myocytes were purchased from ZENBIO (Research Triangle Park, NC, USA) and cultured in medium supplemented with OM-AM, ZENBIO, hepatocyte- (SKM-D, SKM-M, ZENBIO) in a 5% CO 2 incubator. Each cell was treated with 20, 50, and 100 μM Syringal lysinol dissolved in DMSO for 24 hours, and negative control was treated with DMSO at a volume of 1/1000.
각 시료를 처리한 세포들을 차가운 PBS로 2 회 세척한 후, 트리졸 시약(TRIzol agent, Invitrogen)을 이용하여 그로부터 RNA를 추출하였다. 상기에서 추출하여 정량한 5 mg의 RNA로 역전사 시스템(Fermentas, Glen Burnie, MD, USA)을 이용하여 cDNA를 합성하였다. 합성된 cDNA 및 SIRT 1과 GAPDH의 각 유전자에 대해 미리 디자인된 프라이머(primer)를 이용하여 각 유전자들의 발현 양상을 qRT-PCR로 측정하였다. PCR 반응과 분석은 로터-진 3000 시스템(Rotor-Gene 3000 system; Corbett Research, Sydney, Australia)을 이용하였다. mRNA 상대적 발현 결과를 도 3에 나타내었다.Cells treated with each sample were washed twice with cold PBS, and RNA was extracted from them using TRIzol agent (Invitrogen). CDNA was synthesized using 5 mg of RNA extracted and quantified from the above using a reverse system (Fermentas, Glen Burnie, MD, USA). Expression patterns of each gene were determined by qRT-PCR using primers designed for the synthesized cDNA and
도 3에서 볼 수 있듯이, 시링가레시놀은 농도 의존적으로 인간 지방세포, 간세포 및 근세포에서 SIRT 1의 발현을 증가시킬 수 있다. 이를 기초로 시링가레시놀은 대사 이상, 구체적으로 지질 대사 이상을 개선할 수 있음을 알 수 있다.
As can be seen in Fig. 3, Sirling's lycinol can increase the expression of SIRT1 in human adipocytes, hepatocytes and myocytes in a concentration-dependent manner. Based on this, it can be seen that siringagrelinol can improve metabolism abnormality, specifically lipid metabolism abnormality.
[실험예 2] 지방세포 및 간세포에서 지방 대사 관련 유전자 발현 조절능 평가[Experimental Example 2] Evaluation of regulation of lipid metabolism-related gene expression in adipocytes and hepatocytes
실험예 1과 실질적으로 동일한 방법으로 인간 지방세포, 간세포 및 근세포에 50 μM 시링가레시놀을 처리한 후 PBS로 세척하고, RNA를 추출하여 cDNA를 합성하였다. ADD1/SREBP1c, ACC, FAS 등의 지방산 합성 관련 유전자들 및 ACO, CPT1, mCAD 등의 지방산 산화 관련 유전자들의 발현 양상 변화를 qRT-PCR을 이용하여 측정하였다. 시료로 DMSO만을 처리한 대조군과 비교한 결과를 도 4 내지 도 9에 나타내었다.Human adipocytes, hepatocytes and myocytes were treated with ringgarcinol at 50 [mu] M in the same manner as in Experimental Example 1, washed with PBS, and RNA was extracted to synthesize cDNA. Expression patterns of fatty acid synthesis-related genes such as ADD1 / SREBP1c, ACC, and FAS and fatty acid oxidation-related genes such as ACO, CPT1, and mCAD were measured using qRT-PCR. The results of comparison with the control group treated with DMSO only as a sample are shown in Figs.
도 4 내지 도 6에서 볼 수 있듯이, 시링가레시놀은 지방산 합성을 유도하는 유전자들의 발현을 억제하였다. 또한 도 7 내지 도 9에서 볼 수 있듯이, 시링가레시놀은 지방산 산화를 촉진하는 유전자들의 발현을 증가시켰다. 이를 토대로, 시링가레시놀은 지방 합성을 저해함과 동시에 지방 소비를 증가시켜 지방 축적을 억제할 수 있음을 알 수 있다.
As can be seen from Figs. 4 to 6, Sirling's rescinol inhibited the expression of genes inducing fatty acid synthesis. As can also be seen from Figs. 7 to 9, siring ginsenosin increased the expression of genes promoting fatty acid oxidation. Based on these results, it can be seen that Sirring regicin inhibits lipid synthesis and increases fat consumption and inhibits fat accumulation.
[실험예 3] 지방산 산화 촉진능 평가[Experimental Example 3] Evaluation of fatty acid oxidation promoting ability
실험예 1과 실질적으로 동일한 방법으로 50 μM 시링가레시놀을 인간 지방세포, 간세포 및 근육세포에 처리하였다. 세포를 PBS로 세척한 다음 지방산 산화 측정용 배지에서 하루간 배양한 후 배지를 걷어 안에 함유된 3H2O의 양을 측정하였다. 무처리군과 대비한 결과를 도 10에 나타내었다.In a substantially same manner as in Experimental Example 1, ringer recipin was treated at 50 [mu] M to human adipocytes, hepatocytes and muscle cells. Cells were washed with PBS, cultured in a fatty acid oxidation assay medium for one day, and the amount of 3 H 2 O contained in the medium was measured by counting the medium. The results are shown in Fig. 10 in comparison with the untreated group.
도 10에서 볼 수 있듯이, 시링가레시놀은 인간 지방세포, 간세포 및 근세포에서 지방산 산화를 증가시킬 수 있다. 이를 기초로 시링가레시놀은 체내 지방 축적을 억제할 수 있음을 알 수 있다.
As can be seen from Fig. 10, Siringagrelin can increase fatty acid oxidation in human adipocytes, hepatocytes and myocytes. Based on this, it can be seen that siringagrecinol can inhibit accumulation of fat in the body.
[실시예 5] 시링가레시놀의 PGC 1 발현 증가 효과[Example 5] Increase in expression of
실험예 1과 실질적으로 동일한 방법으로 50 μM 시링가레시놀을 인간 지방세포, 간세포 및 근세포에 처리한 후 PBS로 세척하고 RNA 및 cDNA를 순차적으로 추출하였다. 에너지 대사에 관련된 유전자들의 발현을 조절하는 PGC 1α 및 PGC 1β의 mRNA 발현을 전용 프라이머를 이용하여 qRT-PCR로 분석하였다. 시료로 DMSO만을 처리한 대조군과 비교한 PGC 1α 및 PGC 1β의 발현 결과를 각각 도 11 및 도 12에 나타내었다.In a substantially same manner as in Experimental Example 1, ringer recipin was treated with human adipocytes, hepatocytes and myocytes at 50 μM, washed with PBS, and RNA and cDNA were sequentially extracted. MRNA expression of PGC 1α and PGC 1β, which regulate the expression of genes related to energy metabolism, was analyzed by qRT-PCR using a dedicated primer. Expression results of PGC 1α and PGC 1β compared with the control group treated with DMSO alone were shown in FIGS. 11 and 12, respectively.
도 11 및 도 12에서 볼 수 있듯이, 시링가레시놀은 인간 지방세포, 간세포 및 근세포에서 PGC 1α 및 PGC 1β의 발현을 증가시킬 수 있다. 이를 기초로 시링가레시놀은 에너지 대사를 촉진하여 체내 지방 축적을 억제할 수 있음을 알 수 있다.
As can be seen from Figs. 11 and 12, Sirling's recurin can increase the expression of
본 발명의 일측면에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Formulation examples of compositions according to one aspect of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the invention.
[제형예 1] 건강 식품[Formulation Example 1] Health food
시링가레시놀................... 1000 ㎎ Siringa glycine ................... 1000 mg
비타민 혼합물 Vitamin mixture
비타민 A 아세테이트...............70 ㎍ Vitamin A Acetate ............... 70 ㎍
비타민 E ....................... 1.0 ㎎ Vitamin E ....................... 1.0 mg
비타민 B1...................... 0.13 ㎎ Vitamin B1 ...................... 0.13 mg
비타민 B2 ...................... 0.15 ㎎ Vitamin B2 ...................... 0.15 mg
비타민 B6........................ 0.5 ㎎ Vitamin B6 ........................ 0.5 mg
비타민 B12....................... 0.2 ㎍ Vitamin B12 ....................... 0.2 g
비타민 C.......................... 10 ㎎ Vitamin C .......................... 10 mg
비오틴............................. 10 ㎍ Biotin ............................. 10 μg
니코틴산아미드.................... 1.7 ㎎ Nicotinic acid amide ... 1.7 mg
엽산............................... 50 ㎍ Folic acid ............................... 50 ㎍
판토텐산 칼슘..................... 0.5 ㎎ Calcium pantothenate ..................... 0.5 mg
무기질 혼합물 Mineral mixture
황산제1철........................ 1.75 ㎎ Ferrous sulfate ........................ 1.75 mg
산화아연.......................... 0.82 ㎎ Zinc oxide .......................... 0.82 mg
탄산마그네슘...................... 25.3 ㎎ Magnesium carbonate ...................... 25.3 mg
제1인산칼륨......................... 15 ㎎ Potassium Phosphate ......................... 15 mg
제2인산칼슘......................... 55 ㎎ Secondary Calcium Phosphate ..................... 55 mg
구연산칼륨.......................... 90 ㎎ Potassium citrate .......................... 90 mg
탄산칼슘........................... 100 ㎎ Calcium carbonate ........................... 100 mg
염화마그네슘...................... 24.8 ㎎ Magnesium chloride ...................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강 식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with the ingredient suitable for health food as a preferred embodiment, the compounding ratio thereof may be arbitrarily modified.
[제형예 2] 건강 음료[Formulation Example 2] Health drinks
시링가레시놀.......................... 1000 ㎎ Siringa glycine .......................... 1000 mg
구연산................................ 1000 ㎎ Citric acid ................................ 1000 mg
올리고당................................ 100 g Oligosaccharides ................................ 100 g
타우린.................................... 1 g Taurine .................................... 1 g
정제수............ ...................... 잔량 Purified water ............ ...................... Remaining amount
통상의 건강 음료 제조 방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균한다.
The above components are mixed according to a conventional health drink manufacturing method, and the mixture is stirred and heated at 85 DEG C for about 1 hour, and then the solution is sterilized by filtration.
[제형예 3] 정제[Formulation Example 3] Tablets
시링가레시놀 100 mg, 대두 추출물 50 mg, 포도당 100 mg, 홍삼 추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하고 타정기를 이용하여 정제로 타정한다.
100 mg of siringagrecinol, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate were mixed and 40 mg of 30% ethanol was added to form granules, Dry and tablet with tablets using a tablet machine.
[제형예 4] 과립제[Formulation Example 4]
시링가레시놀 100 mg, 대두 추출물 50 mg, 포도당 100 mg 및 전분 600 mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하여 과립을 형성한 다음 포에 충진한다.
100 mg of siringagrecinol, 50 mg of soybean extract, 100 mg of glucose and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C to form granules, .
[제형예 5] 크림[Formulation Example 5] Cream
아래 표에 기재된 조성으로 통상의 방법에 따라 크림을 제조한다.Creams are prepared according to a conventional method with the composition shown in the following table.
Claims (8)
A composition for preventing or ameliorating a lipid metabolism disorder comprising syringaresinol as an active ingredient.
지질 대사 이상증은 비만, 고지혈증 및 지방간으로 이루어진 군에서 선택된 하나 이상을 포함하는 조성물.
The method according to claim 1,
Wherein the lipid metabolism disorder comprises at least one selected from the group consisting of obesity, hyperlipidemia and fatty liver.
시링가레시놀은 아마씨, 황백, 가시오가피, 참깨 및 인삼 열매 중 선택된 하나 이상의 추출물로부터 분리되는 것인 조성물.
The method according to claim 1,
Wherein the singing griseol is separated from one or more extracts selected from flaxseed, white, white, sesame and ginseng.
조성물은 조성물 전체 중량을 기초로 1 중량% 내지 80 중량%의 시링가레시놀을 포함하는 조성물.
The method according to claim 1,
Wherein the composition comprises from 1% to 80% by weight, based on the total weight of the composition, of a syringal lysinol.
조성물은 지방산 합성을 억제하고, 지방산 산화를 촉진하는 조성물.
The method according to claim 1,
The composition inhibits fatty acid synthesis and promotes fatty acid oxidation.
조성물은 식품 조성물인 조성물.
7. The method according to any one of claims 1 to 6,
Wherein the composition is a food composition.
조성물은 약학 조성물인 조성물.7. The method according to any one of claims 1 to 6,
Wherein the composition is a pharmaceutical composition.
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110108904A KR101866924B1 (en) | 2011-10-24 | 2011-10-24 | Composition for improving metabolism disorder comprising syringaresinol |
CN201610134626.0A CN105708834A (en) | 2011-10-18 | 2012-10-18 | Sirt1 activator including syringaresinol |
CN201610134625.6A CN105796546B (en) | 2011-10-18 | 2012-10-18 | SIRT1 activator containing syringaresinol |
CN201280062749.8A CN104093406B (en) | 2011-10-18 | 2012-10-18 | Include the SIRT1 activators of syringaresinol |
CN201610133542.5A CN105708833A (en) | 2011-10-18 | 2012-10-18 | Sirt 1 activator including syringaresinol |
JP2014536990A JP6126107B2 (en) | 2011-10-18 | 2012-10-18 | SIRT-1 activator containing syringaresinol |
PCT/KR2012/008556 WO2013058579A1 (en) | 2011-10-18 | 2012-10-18 | Sirt 1 activator including syringaresinol |
US14/352,444 US9913823B2 (en) | 2011-10-18 | 2012-10-18 | SIRT 1 activator including syringaresinol |
US15/160,239 US10022351B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
US15/160,218 US11096921B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
US15/160,197 US9999611B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
JP2016213315A JP6310991B2 (en) | 2011-10-18 | 2016-10-31 | SIRT-1 activator containing syringaresinol |
JP2016213317A JP6463320B2 (en) | 2011-10-18 | 2016-10-31 | SIRT-1 activator containing syringaresinol |
JP2016213316A JP6234536B2 (en) | 2011-10-18 | 2016-10-31 | SIRT-1 activator containing syringaresinol |
HK16114645A HK1226305A1 (en) | 2011-10-18 | 2016-12-23 | Sirt 1 activator including syringaresinol |
HK16114643A HK1226303A1 (en) | 2011-10-18 | 2016-12-23 | Sirt 1 activator including syringaresinol |
HK16114644A HK1226304A1 (en) | 2011-10-18 | 2016-12-23 | Sirt 1 activator including syringaresinol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110108904A KR101866924B1 (en) | 2011-10-24 | 2011-10-24 | Composition for improving metabolism disorder comprising syringaresinol |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130044707A KR20130044707A (en) | 2013-05-03 |
KR101866924B1 true KR101866924B1 (en) | 2018-06-15 |
Family
ID=48657043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110108904A KR101866924B1 (en) | 2011-10-18 | 2011-10-24 | Composition for improving metabolism disorder comprising syringaresinol |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101866924B1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102905714A (en) | 2010-03-31 | 2013-01-30 | 株式会社爱茉莉太平洋 | Composition comprising coumestrol or bean extract containing coumestrol |
-
2011
- 2011-10-24 KR KR1020110108904A patent/KR101866924B1/en not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
Biomolecules and Therapeutics 18(2):211-218(2010 * |
Biomolecules and Therapeutics 18(2):211-218(2010* |
Biomolecules and Therapeutics 18(2):211-218(2010.) 1부. * |
Also Published As
Publication number | Publication date |
---|---|
KR20130044707A (en) | 2013-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101434653B1 (en) | Novel use of flavon compounds | |
KR100653948B1 (en) | Ikappa;B KINASE INHIBITOR AND Ikappa;B KINASE INHIBITING COMPOSITION COMPRISING THEREOF | |
CN104093406B (en) | Include the SIRT1 activators of syringaresinol | |
KR20160139072A (en) | Pharmaceutical composition comprising Ptentilla Chinensis extract or isolated polyphenolic compounds for prevention or treatment of metabolic disease | |
CN114907202B (en) | Preparation and application of active extract of fructus Zanthoxyli, fructus Zanthoxyli polyphenol and its composition | |
KR101865059B1 (en) | Anti-aging composition comprising aster plant extracts | |
KR20170002846A (en) | Composition containing extract of soybean leaves for suppressing and preventing myopathy | |
KR101758144B1 (en) | Composition for anti-aging containing youngia denticulata extract | |
KR101924054B1 (en) | Composition for improving or treating atopic dermatitis comprising a novel compound stechamone isolated from Stellera chamaejasme extracts as active ingredient | |
JP6184414B2 (en) | Composition for inhibiting vascular aging containing syringaresinol | |
KR101866924B1 (en) | Composition for improving metabolism disorder comprising syringaresinol | |
KR101894986B1 (en) | Composition for preventing or improving metabolic syndrome comprising tea plant leaf, flower and seed extract | |
KR20130092367A (en) | Lignan compound derived from kadsura coccinea and method of obtaining thereof | |
KR101866925B1 (en) | Composition for improving eye disease comprising syringaresinol | |
JP2017052750A (en) | Novel ellagitannins and agents for oral applications | |
KR101473748B1 (en) | A Composition for Improving Obesity and Hyperlipidemia Using an Extract of Crinum asiaticum | |
KR101601843B1 (en) | A composition for anti-obesity comprising saringosterol | |
KR20150012164A (en) | Composition for Anti-obesity Using Fucoxanthin Derivatives | |
KR20130009238A (en) | Composition for improving skin diseases | |
KR20180068914A (en) | Composition for inhibition of aging comprising syringaresinol | |
KR20130045631A (en) | Composition for improving immunological disease comprising syringaresinol | |
KR101870210B1 (en) | Anti-aging composition comprising aster plant extracts | |
KR101986008B1 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising extract of resveratrol-enriched rice or resveratrol enriched rice callus as an active ingredient | |
KR101829331B1 (en) | Composition for detoxification comprising syringaresinol | |
CN116041208A (en) | Lycium barbarum root polyphenol derivative composition, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal |